v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Net sales $ 2,444 $ 2,206 $ 4,656 $ 4,230
Operating expenses:        
Cost of sales 2,123 1,943 4,091 3,718
Selling, general and administrative 100 104 197 209
Amortization 0 1 1 1
Restructuring (Note 9) 0 25 46 41
Separation costs 22 2 48 7
Total operating expenses 2,245 2,075 4,383 3,976
Operating income 199 131 273 254
Interest expense (36) (1) (41) (3)
Other expense, net (Note 18) (6) 0 (7) (1)
Income before income taxes and equity income 157 130 225 250
Income tax expense (Note 13) (46) (21) (37) (50)
Income before equity income 111 109 188 200
Equity income, net of tax 5 3 9 8
Net income 116 112 197 208
Net (loss) income attributable to noncontrolling interest (2) 5 1 6
Net income attributable to Versigent $ 118 $ 107 $ 196 $ 202
Basic earnings per share:        
Basic earnings per share attributable to Versigent (in usd per share) $ 1.66 $ 1.51 $ 2.76 $ 2.85
Weighted average number of basic shares outstanding (in shares) 70,900 70,890 70,900 70,890
Diluted earnings per share:        
Diluted earnings per share attributable to Versigent (in usd per share) $ 1.64 $ 1.51 $ 2.75 $ 2.85
Weighted average number of diluted shares outstanding (in shares) 71,880 70,890 71,390 70,890